|
04/29/08 |
Genentech and Biogen Idec Announce Top-Line Results from Phase II/III
Clinical Study of RITUXAN in Systemic Lupus Erythematosus |
|
|
|
|
|
Compugen Announces Discovery of Blood Based Biomarker for Diagnosis of
Lung Cancer |
|
|
|
|
|
Takeda and Millennium Announce Early Termination of Hart-Scott-Rodino
Waiting Period |
|
|
|
|
04/28/08 |
Breakthrough technique pioneered at Novartis research institute restores
light sensitivity in damaged retinas |
|
|
|
|
04/25/08 |
Medarex and Bristol-Myers Squibb Joint Statement on Submission Status of
Ipilimumab |
|
|
|
|
|
GSK receives positive opinion for conditional approval of new oral
breast cancer treatment, Tyverb (lapatinib) |
|
|
|
|
04/24/08 |
High court slashes $200 million from Genetech judgment |
|
|
|
|
|
Amgen first-quarter profit is nearly flat on declining sales |
|
|
|
|
|
BMS:
Strong Double-Digit Net Sales Growth and Solid Earnings Growth Highlight
First Quarter for Bristol-Myers Squibb Company |
|
|
|
|
|
Thermo Fisher Scientific Reports Record 2008 First Quarter Revenues and
Operating Performance |
|
|
|
|
04/23/08 |
Novartis announces 20% average reduction in price of malaria drug
Coartem® to further accelerate access in malaria-endemic regions |
|
|
|
|
04/21/08 |
Novartis reports higher sales and earnings in first quarter of 2008
showing healthcare portfolio well on the way to new growth cycle |
|
|
|
|
04/20/08 |
Genentech Provides Update on "AVAiL" Phase III Study of Avastin Plus
Chemotherapy in First-Line, Advanced, Non-Squamous, Non-Small Cell Lung
Cancer |
|
|
|
|
04/17/08 |
Bristol-Myers Squibb to Announce Results for the First Quarter of 2008
on April 24 |
|
|
|
|
04/17/08 |
Abbott Reports Double-Digit Sales and Earnings Growth in First Quarter
and Reaffirms Full-Year Growth Outlook |
|
|
|
|
|
Abbott Announces HUMIRA® (adalimumab) Approved in Japan for the
Treatment of Rheumatoid Arthritis |
|
|
|
|
04/15/08 |
Roche fully acquires
privately-owned biotech company Piramed |
|
|
|
|
04/14/08 |
Genentech and Biogen Idec Announce Top-Line Results From a Phase II/III
Clinical Trial of Rituxan in Primary-Progressive Multiple Sclerosis |
|
|
|
|
04/11/08 |
Novartis
ASA404, a novel cancer agent, begins pivotal trial to explore new
approach in treating lung cancer, the leading cause of cancer death |
|
|
|
|
|
Lilly:
ALIMTA® (pemetrexed for injection) Receives European Approval for
Histologically-Based Use in First-Line Treatment of Most Common Lung
Cancer |
|
|
|
|
|
Vermillion Announces Issuance of U.S. Patent Covering the Discovery of
Novel Forms of Brain Natriuretic Peptide |
|
|
|
|
04/10/08 |
Takeda to Acquire Millennium for US$25.00 Per Share in an All Cash
Tender Offer Valued at $8.8 Billion |
|
|
|
|
04/08/08 |
Novartis:
ACZ885, a new biological drug in development, shows potential in
treating serious life-long autoinflammatory diseases |
|
|
|
|
04/07/08 |
Thermo Fisher Scientific Introduces New Catalog for China |
|
|
|
|
|
Novartis to further strengthen its healthcare portfolio by acquiring 25%
stake in Alcon |
|
|
|
|
04/04/08 |
GSK:
FDA approves Rotarix [Rotavirus Vaccine, live, oral], the first vaccine
licensed to complete the rotavirus immunisation series by four months of
age |
|
|
|
|
04/03/08 |
Thermo Fisher Scientific Receives FDA Clearance for MRSA Test Medium |
|
|
|
|
|
Medarex Announces Ipilimumab Program Continues to Move Forward |
|
|
|
|
04/02/08 |
Amgen:
Pivotal Phase 3 Data Show Denosumab Increased Bone Density at Multiple
Skeletal Sites in Early and Later Stage Postmenopausal Women |
|
|
|
|
03/24/08 |
BMS:
BARACLUDE® (entecavir) Data Continue to Demonstrate Low Incidence of
Resistance Through Five Years of Treatment in Nucleoside-naive Chronic
Hepatitis B Patients
- Data Indicate Pre-existing Lamivudine Resistance Predisposes Patients
to Higher Rates of BARACLUDE Resistance |
|
|
|
|
|
Biogen Idec:
Researchers Report Neublastin Virtually Restores Complete Long-Term
Sensory Motor Function in Preclinical Studies |
|
|
|
|
03/20/08 |
Medarex Receives Milestone Payment for Submission of Regulatory
Application Requesting Approval of Golimumab (CNTO 148) in Europe for
the Treatment of Rheumatoid Arthritis, Psoriatic Arthritis and
Ankylosing Spondylitis |
|
|
|
|
03/19/08 |
Merck:
Supplemental Application for GARDASIL®, Merck's Cervical Cancer Vaccine,
Designated Priority Review by the U.S. FDA for Use in Women 27 through
45 |
|
|
|
|
03/17/08 |
Millennium Expands IBD Franchise with Addition of New Development
Candidate |
|
|
|
|
|
Amgen and Wyeth Announce Updates to U.S. Prescribing Information for
Enbrel(R) |
|
|
|
|
03/13/08 |
Publication of Clinical Results Underscores VELCADE(R) (Bortezomib) For
Injection Based Therapy As a Standard of Care In Newly Diagnosed
Multiple Myeloma Patients |
|
|
|
|
03/11/08 |
Geron:U.S.
Patent Office Upholds Two Additional Human Embryonic Stem Cell Patents
in Reexamination Decisions |
|
|
|
|
03/10/08 |
Novartis:
Femara® helps protect against return of breast cancer even when
treatment starts several years after completing tamoxifen therapy |
|
|
|
|
03/07/08 |
Lilly Announces Termination of AIR Insulin Program |
|
|
|
|
03/06/08 |
Thermo
Fisher Scientific Extends LTQ Orbitrap Mass Spectrometry Performance in
Proteomics with ETD and MALDI Capabilities |
|
|
|
|
|
Merck's ISENTRESS® (raltegravir) Tablets in Combination with other
Anti-HIV Medicines Maintained Reductions in HIV-1 Viral Load and
Increased CD4 Cell Counts Through 48 Weeks of Therapy in
Treatment-Experienced Adults |
|
|
|
|
03/03/08 |
Thermo Fisher Scientific Showcases Product Innovation at PITTCON 2008 |
|
|
|
|
|
GSK:
FDA grants Priority Review For Promacta / Revolade (Eltrombopag),
eltrombopag would be the first oral thrombopoeitin (TPO) receptor
agonist |
|
|
|
|
02/29/08 |
Roche:
Herceptin approved in
Japan for early treatment in patients with HER2-positive breast cancer |
|
|
|
|
|
Update on GSK's malaria treatments: Dacart and Lapdap |
|
|
|
|
02/28/08 |
Novartis:
Everolimus (RAD001) significantly extends progression-free survival in
advanced kidney cancer patients after failure of other targeted therapy |
|
|
|
|
02/23/08 |
FDA approves Avastin to treat breast cancer , link to
article at The San Francisco Chronicle |
|
|
|
|
|
Roche:
FDA grants accelerated
approval of Avastin in combination with paclitaxel chemotherapy for
first-line treatment of patients with advanced HER2-negative breast
cancer |
|
|
|
|
02/18/08 |
Thermo Scientific LTQ Orbitrap™
Mass Spectrometer Selected for Ground-Breaking Research in Disease
Treatment and Prevention |
|
|
|
|
02/08/08 |
GeneBio Announced the Release of
Version 7.0 of the Renowned Melanie 2-D Gel Analysis Platform. |
|
|
|
|
02/06/08 |
Thermo Fisher Scientific Reports Record 2007 Fourth Quarter Revenues and
Operating Performance; Provides Guidance for 2008 |
|
|
|
|
|
GSK:
GlaxoSmithKline responds to findings in ACCORD study |
|
|
|
|
|
Lilly:
FDA Advisory Committee Supports Efficacy and Safety of Zyprexa®
Long-Acting Injection (LAI) for Schizophrenia Treatment |
|
|
|
|
|
BMS:
CASTLE Study Showed Similar Efficacy Between Once-Daily REYATAZ® (atazanavir
sulfate)/ritonavir and Twice-Daily lopinavir/ritonavir at 48 Weeks in
Previously Untreated HIV-Infected Adult Patients
Data also showed differences in gastrointestinal and lipid effects
between REYATAZ/ritonavir and lopinavir/ritonavir among study population |
|
|
|
|
|
Amgen:
Amgen and Takeda Announce Exclusive Collaboration in Japan on up to 13
Amgen Clinical Candidates |
|
|
|
|
|
Applied Biosystems Expands Line of Labeling Chemistry Reagents to Help
Improve Proteomics Research |
|
|
|
|
02/05/08 |
Geron’s Second U.S.
Patent for Production of Pancreatic Islets From Human Embryonic Stem
Cells Strengthens Company’s Intellectual Property Position |
|
|
|
|
02/01/08 |
Novartis:
Galvus®, a new treatment for patients with type 2 diabetes, receives
European approval for label update paving the way for EU launches |
|
|
|
|
|
Amgen:
New Findings Show Enbrel(R) (etanercept) Significantly Reduced Levels of
C-Reactive Protein, a Marker of Inflammation, in Patients with Moderate
to Severe Plaque Psoriasis |
|
|
|
|
01/31/08 |
Research Using Thermo Fisher Scientific RNA-Interference Technology
Unveils Potential New Targets for HIV Drugs |
|
|
|
|
01/30/08 |
Millenium:
FDA Grants Priority Review For Velcade(R) (bortezomib) for Injection In
Patients with Newly Diagnosed Multiple Myeloma |
|
|
|
|
|
Roche:
Record operating
results for Roche again in 2007 |
|
|
|
|
01/29/08 |
Thermo Fisher Scientific to Present at the 2008 Merrill Lynch Global
Pharmaceutical, Biotechnology & Medical Device Conference |
|
|
|
|
|
Myriad Genetics
Announces Completion of Phase 1 Trial of Anti-Thrombin Drug MPC-0920 |
|
|
|
|
|
Merck:
FDA Approves EMEND® (fosaprepitant dimeglumine) for Injection, Merck's
New Intravenous Therapy, for Use in Combination with Other Antiemetics
for Prevention of Nausea and Vomiting Caused by Chemotherapy |
|
|
|
|
|
CuraGen Corporation Receives Notification from NASDAQ |
|
|
|
|
01/28/08 |
Avastin receives broad
label extension in Europe for the treatment of patients with metastatic
colorectal cancer |
|
|
|
|
01/24/08 |
Genentech and Biogen Idec Announce Positive Results from a Phase III
Trial of Rituxan in Patients With Rheumatoid Arthritis Who Inadequately
Responded to Methotrexate |
|
|
|
|
01/21/08 |
Novartis:
Tekturna HCT®, a single-tablet combination of Tekturna®* and a diuretic,
receives US approval for treatment of high blood pressure |
|
|
|
|
01/19/08 |
VC Investments Rise to Six-Year High, link to article at The San
Francisco Chronicle |
|
|
|
|
01/18/08 |
Human embryos created from skin - Personalized stem cells are aim of
work, La Jolla firm says, link to article at The San Francisco
Chronicle |
|
|
|
|
|
Roche invests 430
million Swiss francs at sites in Germany and Switzerland |
|
|
|
|
|
Bristol-Myers Squibb Announces Closing of Its Barceloneta, Puerto Rico
Plant |
|
|
|
|
|
Abbott's HUMIRA® (adalimumab) Receives FDA Approval for Moderate to
Severe Chronic Plaque Psoriasis |
|
|
|
|
01/17/08 |
Novartis achieves record results in 2007 underscoring benefits of
strategic healthcare portfolio |
|
|
|
|
01/16/08 |
GeneBio's Phenyx Tapped by Chinese
State Key Laboratory of Proteomics |
|
|
|
|
01/15/08 |
GlaxoSmithKline and XenoPort report positive top-line results of second
phase 3 restless legs syndrome trial for XP13512/GSK1838262 |
|
|
|
|
01/08/08 |
Medarex Announces Allowance of Investigational New Drug Application for
Wholly Owned Fully Human Anti-CD70 Antibody, MDX-1411 |
|
|
|
|
|
Lilly:
FDA Approves Cialis® (tadalafil) for Once Daily Use for the Treatment of
Erectile Dysfunction |
|
|
|
|
|
Avista Capital Partners Completes Acquisition of Bristol-Myers Squibb
Medical Imaging |
|
|
|
|
|
Biogen
Idec and PDL BioPharma License the Rights to Develop Volociximab in
Ophthalmic Indications to Ophthotech |
|
|
|
|
01/04/08 |
Millennium Announces 2008 Goals for Growth, Building on Record 2007
Results |
|
|
|
|
01/03/08 |
GlaxoSmithKline and Theravance announce start of large Phase 2B ICS and
LABA studies for asthma in the Horizon programme |
|
|
|
|
|
Bruker AXS Announces Agreement to Acquire Elemental Analysis Company
JUWE Laborgeraete GmbH |
|
|
|
|
12/20/07 |
Thermo Fisher Scientific Acquires Leading Chromatography Consumables
Provider, La-Pha-Pack |
|
|
|
|
|
CuraGen Corporation Announces Appointment of Sean Cassidy as CFO |
|
|
|
|
12/19/07 |
Applied Biosystems Promotes Mark Stevenson to President and Chief
Operating Officer |
|
|
|
|
|
Roche:
Avastin approved in
Europe for first-line treatment of patients with advanced kidney cancer |
|
|
|
|
|
CuraGen and TopoTarget Announce Initiation of an NCI-sponsored Phase II
Clinical Trial of Belinostat for Thymoma and Thymic Carcinoma |
|
|
|
|
|
Biogen
Idec Announces First Startup in its Innovation Incubator |
|
|
|
|
12/17/07 |
GlaxoSmithKline receives FDA ‘complete response’ letter for cervical
cancer vaccine |
|
|
|
|
|
BMS:
Avista Capital Partners Agrees to Acquire Bristol-Myers Squibb Medical
Imaging for Approximately $525 Million |
|
|
|
|
12/16/07 |
GlaxoSmithKline announces data on Tykerb ® (lapatinib) plus capecitabine
for the treatment of HER2-positive breast cancer brain metastases
|
|
|
|
|
12/13/07 |
Biogen Says It Plans to Stay Independent, link to
article at The San Francisco Chronicle |
|
|
|
|
12/12/07 |
Geron Receives
Milestone Payment From Merck Triggered by IND Filing for Telomerase
Cancer Vaccine Candidate |
|
|
|
|
|
Biogen
Idec Completes Review of Strategic Alternatives, Company to Remain
Independent |
|
|
|
|
12/10/07 |
GlaxoSmithKline and OncoMed Pharmaceuticals form strategic alliance to
develop cancer stem cell antibody therapeutics |
|
|
|
|
12/09/07 |
Novartis:
New data show Glivec® halts progression to advanced stages of
life-threatening form of leukemia in sixth year of treatment |
|
|
|
|
|
Millenium:
Phase III Trial of VELCADE(R) (Bortezomib) for Injection Showed Dramatic
Fourfold Increase in Complete Remission Rates When Combined With the
Most Commonly Used U.S. Regimen in Front-Line Multiple Myeloma |
|
|
|
|
12/08/07 |
Amgen:
Pivotal Phase 3 Romiplostim Study in Splenectomized Patients Meets
Primary Endpoints |
|
|
|
|
12/05/07 |
Genentech Provides Update From Avastin FDA Advisory Meeting |
|
|
|
|
12/04/07 |
Myriad Genetics
Submits IND on Vivecon |
|
|
